ArticleCureus2025
Effect of Esaxerenone in Patients With Persistent Atrial Fibrillation and Hypertension After Catheter Ablation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background In this study, we investigated the effects of esaxerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with persistent atrial fibrillation (AF) and hypertension after they had undergone catheter ablation. Methodology Our retrospective analysis included 157 consecutive patients with this condition. Overall, 40 patients received esaxerenone within three months after catheter ablation (hereafter, the esaxerenone group), and 117 of them did not (hereafter, the non-esaxerenone group). Other conventional pharmacologic agents were used similarly in the two groups. Results The rate of freedom from AF at one year was not significantly different between the two groups (80% (n = 32) vs. 84% (n = 98), p = 0.60). Independent predictors for AF recurrence according to univariate and multivariate Cox regression analysis were the duration of AF history (p < 0.01) and left ventricular myocardial index (LVMI) before ablation (p < 0.01). There was no significant difference in brain natriuretic peptide or LVMI before ablation (p = 0.43 and 0.89) between the groups. However, the esaxerenone group showed lower levels of brain natriuretic peptide at six months after catheter ablation (50.0 (16.3, 83.9) vs. 64.6 (25.9, 132.0) ng/mL, p = 0.02) and significant decrease in LVMI at one year after catheter ablation (-3.8 (-21.7, 3.5) vs. 0.0 (-4.3, 9.9) g/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.